This page uses content from Wikipedia and is licensed under CC BY-SA.

Lupitidine

Lupitidine
Lupitidine.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H27N5O2S
Molar mass413.54 g/mol g·mol−1
3D model (JSmol)

Lupitidine (INN; lupitidine hydrochloride (USAN); development code SKF-93479) is a long-acting H2 receptor antagonist[1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed.[2] It was shown to inhibit nocturnal gastric acid secretion[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.[4]

References

  1. ^ Franzén L, Ghassemifar R, Malcherek P (July 1991). "Experimental mast cell activation improves connective tissue repair in the perforated rat mesentery". Agents and Actions. 33 (3–4): 371–7. doi:10.1007/bf01986588. PMID 1683107.
  2. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 745–. ISBN 978-1-4757-2085-3.
  3. ^ Dammann HG, Müller P, Simon B (January 1982). "Inhibition of nocturnal acid secretion by H2-receptor-antagonist SKF 93479". Lancet. 1 (8265): 224. doi:10.1016/S0140-6736(82)90788-7. PMID 6119582.
  4. ^ Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P (1 February 1988). "Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole". Toxicologic Pathology. 16 (2): 288–98. doi:10.1177/019262338801600222. PMID 2903544.